Letter from the Editor

Dear Colleagues,

 

Thank you for your interest in this edition of Medicom’s Conference Report covering the American College of Cardiology Scientific Session occurring in New Orleans, USA, in March of 2023. This year’s meeting was filled with late-breaking clinical trials, innovative science and new developments in structural cardiology.

 

In the following pages, you can read about outcomes from latest clinical trials, including new advances in lipid lowering therapy such as improved outcomes with bempedoic acid in the landmark CLEAR OUTCOMES trial and new encouraging data for oral PCSK9 inhibitors. Late-breaking data were also presented for sotatercept showing improved outcomes in patients with pulmonary hypertension. In addition, new data regarding catheter-based therapies for mitral and tricuspid valve disease as well as data on the durability of TAVR were presented.  As always, our summaries are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.

 

Sincerely,

 

Marc Bonaca

 



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi



Posted on 8 June, 20234 July, 2023